Product Description
KFA-115, also known as NVP-KFA115, is an immunomodulatory agent being developed by Novartis for the treatment of select advanced cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05544929?term=KFA-115&draw=2&rank=1)
Mechanisms of Action: Immunomodulator
Novel Mechanism: No
Modality: N/A
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea, Singapore, Spain, Taiwan, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Anus Cancer|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Melanoma|Mesothelioma|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Renal Cell Carcinoma|Squamous Cell Carcinoma|Thymoma|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CKFA115A12101 | P1 |
Recruiting |
Renal Cell Carcinoma|Thymoma|Melanoma|Nasopharyngeal Cancer|Esophageal Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Head and Neck Cancer|Cutaneous Squamous Cell Carcinoma|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Gastrointestinal Cancer|Anus Cancer|Mesothelioma |
2027-09-01 |
4% |
| jRCT2031230410 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2025-12-31 |
|
| CTR20250770 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
None |